H L Tremlett1, J Evans, C M Wiles, D K Luscombe. 1. Department of Medicine (Neurology), University of Wales College of Medicine, Cardiff, Wales, UK. tremlett@interchange.ubc.ca
Abstract
BACKGROUND: Th1/Th2 imbalance is hypothesized to up-regulate some diseases and down-regulate others. Compared to controls, multiple sclerosis (MS) (Th1-mediated) has been linked to a reduced risk of allergy and asthma (Th2-mediated), based on patient questionnaire studies and a review of asthma medication. AIM: To investigate whether MS is associated with a reduced risk of Th2-associated diseases and an increased risk of Th1-associated diseases. DESIGN: Retrospective matched case-control study. METHODS: Three hundred and twenty MS patients and controls matched for age, gender, location and smoking were selected from the Welsh General Practice Morbidity Database from 1995-99. Case and control records were assessed for Th1-mediated and Th2-mediated diseases. RESULTS: Overall, 346 MS patients were identified, giving a prevalence of 127 per 100 000. There was an inverse relationship between multiple sclerosis (MS) and asthma (OR 0.33; 95%CI 0.15-0.77). No statistically significant relationships emerged between other Th2-associated (eczema, dermatitis) or any Th1-associated (rheumatoid arthritis, thyroid disorders, inflammatory bowel disease [IBD], type 1 diabetes) diseases and MS, although no patient in either group had treated type 1 diabetes. A trend existed for IBD, with 5/320 of cases affected and no controls; OR infinity; 95%CI 1.30-infinity; p=0.063. DISCUSSION: This inverse association between MS and asthma is compatible with a Th1/Th2 imbalance. Although the Th1/Th2 theory is probably an over-simplification in MS, a shift from Th1 cytokine dominance towards Th2 may provide drug-targeting routes for MS.
BACKGROUND:Th1/Th2 imbalance is hypothesized to up-regulate some diseases and down-regulate others. Compared to controls, multiple sclerosis (MS) (Th1-mediated) has been linked to a reduced risk of allergy and asthma (Th2-mediated), based on patient questionnaire studies and a review of asthma medication. AIM: To investigate whether MS is associated with a reduced risk of Th2-associated diseases and an increased risk of Th1-associated diseases. DESIGN: Retrospective matched case-control study. METHODS: Three hundred and twenty MS patients and controls matched for age, gender, location and smoking were selected from the Welsh General Practice Morbidity Database from 1995-99. Case and control records were assessed for Th1-mediated and Th2-mediated diseases. RESULTS: Overall, 346 MS patients were identified, giving a prevalence of 127 per 100 000. There was an inverse relationship between multiple sclerosis (MS) and asthma (OR 0.33; 95%CI 0.15-0.77). No statistically significant relationships emerged between other Th2-associated (eczema, dermatitis) or any Th1-associated (rheumatoid arthritis, thyroid disorders, inflammatory bowel disease [IBD], type 1 diabetes) diseases and MS, although no patient in either group had treated type 1 diabetes. A trend existed for IBD, with 5/320 of cases affected and no controls; OR infinity; 95%CI 1.30-infinity; p=0.063. DISCUSSION: This inverse association between MS and asthma is compatible with a Th1/Th2 imbalance. Although the Th1/Th2 theory is probably an over-simplification in MS, a shift from Th1 cytokine dominance towards Th2 may provide drug-targeting routes for MS.
Authors: Arne Egesten; Lena Brandt; Tomas Olsson; Fredrik Granath; Malin Inghammar; Claes-Göran Löfdahl; Anders Ekbom Journal: Lung Date: 2008-03-20 Impact factor: 2.584
Authors: R Zivadinov; B Raj; M Ramanathan; B Teter; J Durfee; M G Dwyer; N Bergsland; C Kolb; D Hojnacki; R H Benedict; B Weinstock-Guttman Journal: AJNR Am J Neuroradiol Date: 2016-02-18 Impact factor: 3.825
Authors: Theresa Bourne; Michael Waltz; T C Casper; K Kavak; G Aaen; A Belman; L Benson; M Candee; T Chitnis; J Graves; B Greenberg; M Gorman; Y Harris; L Krupp; T Lotze; S Mar; J Ness; C Olsen; S Roalstad; M Rodriguez; J Rose; J Rubin; T Schreiner; J M Tillema; I Kahn; A Waldman; L Barcellos; E Waubant; B Weinstock-Guttman Journal: J Neurol Sci Date: 2017-02-20 Impact factor: 3.181
Authors: A-L Ponsonby; T Dwyer; I van der Mei; A Kemp; L Blizzard; B Taylor; T Kilpatrick; R Simmons Journal: Clin Exp Immunol Date: 2006-12 Impact factor: 4.330